Mediastinal lymphoma: Quantitative changes in gadolinium enhancement at MR imaging after treatment

Radiology

Volumn 219, Issue 3, 2001, Pages 621-628

  Rahmouni, Alain ^a   Divine, Marine ^a   Lepage, Eric ^a   Jazaerli, Nedal ^a   Belhadj, Karim ^a   Gaulard, Philippe ^a   Golli, Mondher ^a   Reyes, Felix ^a   Vasile, Norbert ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

67.343; Gadolinium; Hodgkin disease, MR, 67.121411, 67.12143, 67.342; Lymphoma, MR, 67.121411, 67.12143, 67.343; Magnetic resonance (MR), Contrast enhancement, 67.12143; Magnetic resonance (MR), tissue characterization, 67.121411; Mediastinum, Neoplasms, 67.342

Indexed keywords

GADOLINIUM;

ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FOLLOW UP; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; INTERMETHOD COMPARISON; LYMPHOMA; MEDIASTINUM MASS; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REMISSION; SIGNAL DETECTION; TREATMENT OUTCOME;

EID: 0034997733     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.219.3.r01jn06621     Document Type: Article

References (33)

1. Nyman RS, Rehn SM, Glimelius BLG, Hagberg HE, Hemmingsson AL, Sundstrom CJ. Residual mediastinal masses in Hodgkin disease: prediction of size with MR imaging. Radiology 1989; 170:435-440.
2. Lee JKT, Glazer HS. Controversy in the MR imaging appearance of fibrosis. Radiology 1990; 177:21-22.
3. Webb WR. MR imaging of treated mediastinal Hodgkin disease. Radiology 1989; 170:315-316.
4. Rahmouni A, Tempany C, Jone R, Mann R, Yang A, Zerhouni E. Lymphoma: monitoring tumor size and signal intensity with MR imaging. Radiology 1993; 188: 445-451.
5. Hill M, Cunningham D, MacVicar D, et al. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol 1993; 11:2273-2278.
6. Gasparini MD, Balzarini L, Castellani MR, et al. Current role of Gallium scan and magnetic resonance imaging in the management of mediastinal Hodgkin lymphoma. Cancer 1993; 72:577-582.
7. Devizzi L, Maffioli L, Bonfante V, et al. Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. Ann Oncol 1997; 8(suppl 1):S53-S56.
8. Zinzani PL, Zompatori M, Bendandi M, et al. Monitoring bulky mediastinal disease with gallium-67, CT scan, and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1996; 22:131-135.
9. Foss Abrahamsen A, Lien HH, Aas M, et al. Magnetic resonance imaging and 67 gallium scan in mediastinal malignant lymphoma: a prospective pilot study. Ann Oncol 1994; 5:433-436.
10. Husband JES. Mackenzie Davidson memorial lecture 1994: imaging of treated cancer. Br J Radiol 1995; 68:1-12.
11. Spiers ASD, Husband JES, MacVicar AD. Treated thymic lymphoma: comparison of MR imaging with CT. Radioloy 1997; 203:369-376.
12. De Baere T, Vanel D, Shapeero LG, Charpentier A, Terrier P, Di Paola M. Osteosarcoma after chemotherapy: evaluation with contrast material-enhanced subtraction MR imaging. Radiology 1992; 185: 587-592.
13. Dao TH, Rahmouni A, Campana F, Laurent M, Asselain B, Fourquet A. Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imaging. Radiology 1993; 187:751-755.
14. Rahmouni A, Divine M, Mathieu D, et al. MR appearance of multiple myeloma of the spine before and after treatment. AJR Am J Roentgenol 1993; 160:1053-1057.
15. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630-1636.
16. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17:1244-1253.
17. Marquardt DW. An algorithm for least square estimation of non-linear parameters. J Soc Ind Appl Math 1963; 11:431-441.
18. Forsgren G, Nyman R, Glimelius B, Hagberg H, Rehn S, Hemmingsson A. Gd-DTPA-enhanced MR imaging in mediastinal Hodgkin's disease. Acta Radiol 1994; 35:564-569.
19. Rihatti D, Vacca A, Nico M, Fanelli M, Roncali L, Dammacco F. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas: an immunohistochemical and ultrastructural study. Eur J Haematol 1996; 56:45-53.
20. Taylor JS, Tofts PS, Phil D, et al. MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging 1999; 10:903-907.
21. Cazals-Hatem D, Lepage E, Brice P, et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study. Am J Surg rathol 1996; 20:877-88.
22. Nyman R, Forsgren G, Glimelius B. Long-term follow-up of residual mediastinal masses in treated Hodgkin's disease using MR imaging. Acta Radiol 1996; 37:323-326.
23. Rehn SM, Rodriguez M, Bergström SR, Nyman RS, Glimelius BLG. Tumour inhomogeneities on magnetic resonance imaging, a new factor with prognostic information in non-Hodgkin's lymphomas. Leuk Lymphoma 1997; 24:501-511.
24. North LB, Fuller LM, Sullivan Halley JA, et al. Regression of mediastinal Hodgkin disease after therapy: evaluation of time interval. Radiology 1987; 164:599-602.
25. Van Amsterdam JAG, Kluin-Nelemans JC, Van Eck-Smit BLF, Pauwels EKJ. Role of 67Ga scintigraphy in localization of lymphoma. Ann Hematol 1996; 72:202-207.
26. Moog F, Bangarter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-(F-18)-fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795-800.
27. Jerusalem G, Warland V, Najjar F, et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999; 20:13-20.
28. Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med 1999; 40:591-603.
29. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429-433.
30. Cremerius U, Fabry U, Neuerburg J, Zimmy M, Osieka R, Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19:1055-1063.
31. Carmosino L, Di Benedetto A, Feffer S. Thymic hyperplasia following successful chemotherapy. Cancer 1985; 56:1526-1528.
32. Dugdale PE, Miles KA, Kelley BB, Leggett DA. CT measurement of perfusion and permeability within lymphoma masses and its ability to assess grade, activity, and chemotherapeutic response. J Comput Assist Tomogr 1999; 23:540-547.
33. Stroszcynski CR, Hosten N, Oellinger JJ, Spahn G, Amthauer HW, Felix R. Value of MR imaging for the staging and monitoring of patients with lymphoma and bulky disease (abstr). Radiology 1998; 209(P): 401.